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Abstract 
Purpose: To develop a simple vanadometric spectrophotometric method for the assay of timolol.  
Methods: The oxidation reactions were performed at optimum conditions of 3 mL 20 % v/v H2SO4, 6.5 
% w/v ammonium metavanadate, 40 - 60 ºC and 5 min for full colour (blue) development. The proposed 
method was validated in accordance with International Council on Harmonization (ICH) guidelines Q2 
(R1) and applied to assay commercial timolol.  
Results: Oxidation of timolol occurred at 504 nm wavelength. The developed method recovered 99.25 - 
102.00 % of timolol in pre-analyzed formulations and 99.85 - 102.00 % of the manufacturers’ claim in 
commercial samples with RSD < 2 %. Linearity of 2 - 20 ppm (R2 = 0.9995),as well as accuracy, 98 - 
101 %; precision, 0.98 % (intraday) and 1.25 % (interday); robustness, 0.95 %; LOD, 0.256 ppm; LOQ, 
0.425 ppm; and robustness, 0.95 - 1.10 %, were obtained.  
Conclusion: The developed method is simple, sensitive, low-cost, accurate, reproducible, robust and 
rugged, and compares well with some complex methods for assay of timolol maleate in pure and 
dosage forms. 
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Transition element-based compounds have great 
potentials in quality control (QC) of 
pharmaceuticals due to the presence of lone 
electron pair(s), and the consequent ability to 
form complexes with many drugs. Ammonium 
metavanadate (AMV) is a yellow crystalline solid 
that has been used variously as a catalyst for 
alpha-hydroxyphosphonate [1], insulin mimic [2], 
oxidizer and sensor for N-acetyltransferase 
activity in urine analysis post-isoniazid 
administration [3] and is known to exhibit pH-
dependent variable oxidative states of +5 to +2 
due to 3d34s2 configuration of central vanadium 
with colour variations in solution of reductants [4]. 
These unique properties of AMV have been 
utilized in the analysis of many pharmaceutical 
dosage forms and inorganic cations.  
 
Timolol maleate (Scheme 1) is a first generation 
non-selective beta-adrenergic receptor 
antagonist used in the treatment of myocardial 
infarction, migraine, chronic open-angle 
glaucoma, heart attack, angina pectoris and 
ocular hypertension [5]. It is chemically 
designated as (S)-1-[(1, 1-dimethylethyl) amino]-
3-[[4-(4-morpholinyl)-1, 2, 5-thiadiazol-3-yl] oxy]-
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2-propanol (Z)-2-butenedioate (1:1) salt. Timolol, 
in combination with a diuretic, has remained the 
first line drug of choice in a stepped-care 
approach to anti-hypertensive drug therapy and 
has remained among the top prescribed agents 
for management of cardiac disorders among the 
blacks.  
 
The therapeutic importance of timolol 
necessitated development of spectrophotometric 
[6-10], HPLC [11], HPTLC [12], 
chemiluminescence [13], voltammetric [14], 
electrophoretic [15], TLC densitometric [16], 
complexometric by charge transfer [17], RP-
HPLC [18-21] and LC [22] methods for its 
determination in single dosage and/or combined 
forms by analysts.  Most of the reported methods 
require complex instrumentation; delicate sample 
preparation methods, costly reagents, expertise 
and a lot of time.  
 
Literature survey indicated no report(s) of 
developed vanadometric assay method for 
timolol in single or combined forms. Against this 
backdrop, we developed and validated an 
oxidometric spectrophotometric assay method for 
timolol, applied the developed validated method 
for assay of the drug in a single dosage form and 
compared the validation parameters with the 
earlier developed methods of assay. Attempts 
were also made to propose the possible route 
and mechanisms of oxidation; the principle of 






Whatman 0.2 µm membrane filter, 25 mm 
diameter size (Cole-Palmer, Nigeria), U-2900 
double beam UV-visible spectrophotometer, 190 
- 1100 nm, 1.5 nm spectral bandpass (Hitachi 
High-Tech Co, Japan). All the reagents are of 
analytical grade. All the timolol formulations (0.25 
and 0.5 %) used were procured from reputable 




Optimization of experimental variables 
 
The effect of AMV concentration was determined 
by adding aliquot 1.0 mL of 0.5 - 10 % w/v AMV 
to equal volume (1 mL) of 2.5 ppm timolol in 
different test tubes. The nature and concentration 
of acidic medium (H2SO4, HCl, HNO3, H3PO4 and 
HClO3) were studied by adding various volumes 
(0.5 - 6 mL) of concentrated acids and the 
optimum concentration of oxidant to 2.5 ppm 
timolol solution. Optimum temperature was 
determined by carrying out the reaction in a 
thermostatically controlled water bath at different 
temperatures 25 - 100 ºC at the optimum 
conditions so far determined, while the reaction 
time was studied for different periods of time (0- 
60 mins). The stability of the developed colour 
was studied up to 4 h, while the order of addition 
of AMV, acid, and temperature to the drug 
solution were determined appropriately. For each 
variable, the rate of blue colour development and 
the absorbance values recorded at 504 nm were 
used as parameter for selecting optimum 
condition for the analysis. 
 
General timolol assay method 
 
The standard timolol solution (1 mL) was 
transferred into 10 mL calibrated flask and 1 mL 
of the 6.5 % w/v AMV was added. The optimum 
volume (3 mL) of 20 % v/v of H2SO4 was added 
(Table 1). The contents of the flasks were 
thoroughly mixed and the reactions were allowed 
to proceed for different periods of time (Table 1) 
at different temperature (40 - 60 °C), and then 
cooled to room temperature. After completion of 
the reactions, the solutions were completed to 
volume with distilled water. The absorbance of 
the resulting solutions was measured at the λmax 





The proposed method was validated in 
accordance with the ICH guidelines Q2 (R1) for 
linearity, precision, accuracy, limits of detection 
and quantization, interference, ruggedness and 
robustness [9]. The linearity was determined by 
preparing six replicates of standard solution of 
timolol in the range of 2-20 ppm and the 
construction of standard calibration curves using 
the optimum conditions. Regression analysis was 
carried out using least square method. Precision 
was determined by replicate analysis of nine 
different solutions of timolol at 10 ppm and 
estimating the relative standard deviation, RSD. 
Robustness was determined by carrying out the 
reaction at temperature of 40 ºC instead of 50 
ºC, and then 5 % w/v AMV instead of 6.5 % w/v 
to ascertain the influences of AMV concentration 
and temperature variations (or any other 
parameter) on the performance of the proposed 
method while keeping other optimum conditions 
unchanged. The percentage recovery and the 
RSD were determined. Ruggedness was 
performed by carrying out the analysis on 
different days and using two different 
spectrophotometers in different laboratories. The 
percentage recovery and % RSD were 
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determined for day-to-day and laboratory-
laboratory assay. The limit of detection (LOD) 
and limit of quantitation (LOQ) were determined 
using the formula 3S/slope and 10S/slope 
respectively, where S is the standard deviation of 




Recovery studies were carried out by adding a 
10 ppm solution of pre-analyzed timolol eye-drop 
to standard solution of pure timolol at 80, 100 
and 120 % levels [6]. To 1 mL of pre-analyzed 
eye-drop solution in three different test tubes, 
0.8, 1.0 and 1.2 mL of 10 ppm standard solution 
were added to each of the eye-drop solution 
respectively and then 1 mL AMV + 3 mL 
sulphuric acid. The solutions were diluted to 10 
mL volume and assayed. 
 
Analysis of timolol formulations by proposed 
method 
 
A quantity of eye-drop equivalent to 1 mg of 
timolol was accurately measured and transferred 
into a 10 mL volumetric flask, appropriately 
diluted with 1 mL 6.5 % w/v AMV and 3 mL 20 % 
v/v of sulphuric acid, made up to mark with 
distilled water and then warmed to the required 
temperature and allowed some time for colour 
development to finally produce a sample solution 
for UV/VIS spectrophotometric analysis as 
already described. The amount of drug present in 
the sample solution was determined using the 





The preliminary findings (Table 1) showed that 
the absorption intensity of timolol increased 
progressively with increasing concentration of 
AMV and H2SO4, reaction time and temperature 
until the maximum absorbance was obtained. 
However, further increase in the concentration of 
AMV or acid, temperature or time had no effect 
on the absorbance. 
 
The parameters selected as optimum conditions 
(Table 1) were considered as the parameter 
(concentration, time and temperature) at which 
maximum absorbance was obtained or full colour 
development observed in the near plateau region 
of the parameter-absorbance curves. 
 
 
Table 1: Optimization of experimental variables 
 
Parameter Value 
AMV concentration 6.5 % w/v 
Concentration and nature of acid 20 %v/v, H2SO4 3 mL 
Temperature 40-60 ± 0.4-1.6 ºC 
Reaction Time 5.0 ± 0.6 mins 
Complex stability 3.4 ± 0.9 hours 
Order of addition Drug = AMV > H2SO4 > Time = Temperature 
*Values are mean ± SD 
 
Table 2: Parameters of the proposed method validation 
 
Parameter Value Parameter Value 
ʎmax 504 nm Precision 
R2 0.9995 Intra-day (% RSD) 0.98 % 
Slope 0.665 Inter-day (Ruggedness) 1.250-1.251 % 
Intercept 0.0015 Accuracy (Recovery) 98-101 % 
Beer’s limit (Linearity) 2-20 μg/mL Robustness (% RSD) 0.95-1.10 % 
LOD (μg/mL) 0.256-0.921 LOQ (μg/mL) 0.425-1.611 
 
Table 3: Recovery of timolol from pre-analyzed eye-drops 
 
Formulation Amount of 
timolol spiked (%) 
Amount recovered (%) % RSD 
Eye-drop A 80 99.25 ± 1.03 1.28 
100 100.60 ± 0.94 0.96 
120 101.90 ± 0.29 0.11 
Eye-drop B 80 102.00 ± 0.78 .082 
100 99.80 ± 1.00 1.01 
120 99.50 ± 1.01 1.05 
Eye-drop C 80 100.05 ± 0.47 0.66 
100 100.70 ± 0.39 0.13 
120 99.70 ± 1.29 1.90 
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Table 4: Analysis of commercial formulations of timolol 
 






% RSD SD 
Eye-drop A 2.5 2.541 101.65 1.56 1.86 
Eye-drop B 2.5 2.496 99.85 0.87 0.98 




The stability of the complex was observed 
beyond 3.4 h which is an indication that this 
assay could be done for a longer time than usual, 
thereby providing flexibility of the method in 
cases of large scale assay in QC. The order of 
addition was performed to determine effect 
sequence of inclusion of the parameters during 
timolol assay. The result showed that the acidic 
medium should be created first once the drug 
comes in contact with the oxidant before 
adjusting the time or the temperature or both. 
Other acids did not provide intense colour 
development compared to H2SO4. 
 
The result of method validation showed that 
Beer’s law was obeyed at 2 - 20 ppm 
concentration with good correlation coefficient 
(0.9995). The RSD was less than 2 % (0.98 %) 
signifying good reproducibility of the proposed 
method for routine timolol assay. The percentage 
recovery of timolol was 98 - 101 % while the % 
RSD was 1.1 %. Variations of optimum 
parameters did not affect the recovery and RSD 
significantly showing the reliability and flexibility 
of the proposed method of timolol analysis. The 
% RSD obtained for lab-to-lab and day-to-day 
assay were 1.25 and 1.251 respectively showing 
the reproducibility of the proposed method. 
 
Timolol is a morpholine ring-containing (A) β-
adrenoceptor antagonist. Cleavage of the 
morpholine ring constitutes one of the major 
oxidation pathways, aside S-oxidation of 
thiadiazole ring (B) as shown in Scheme 1. 
 
The morpholine cleavage involves two pathways- 
(I) initial oxidative attack on one of the carbon 
atoms adjacent to the nitrogen atom of the 
morpholine ring forming hydroxyl-ether 
intermediates and the timolol ethanolamine and 
(II) cleavage of the morpholine ring of timolol 
occurs prior to oxidative attack at one of the 




















































Scheme 1: Proposed oxidation pathways of timolol maleate 
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further oxidation would form timolol glycine [23]. 
The other route (III) involves S-oxidation 
(sulpoxidation). Theoretically, oxidation of timolol 
via routes I and II represents in vivo metabolic 
pathways and the mechanisms have not been 
established unequivocally [24]. Postulations also 
revealed that the oxidation pathways cannot be 
harnessed ex vivo or in vitro quantitatively to 
warrant its usefulness in the present studies as 
the metabolism (by oxidation) of several drugs 
(including metoprolol and timolol) is linked to the 
debrisoquine oxidation phenotype [24]. Several 
drugs which possess structures (ring B) similar to 
timolol have been found to be oxidized 
quantitatively to its sulphoxide in acidic medium 
[25] suggesting the possibility of timolol oxidation 
via such mechanism. 
The validation parameters of timolol maleate in 
this study compare very well with reported 
parameters of other developed methods, 
suggesting the suitability of this method in the 
routine assay of timolol. The UV detection ʎ 
differs due to the differences in the methods 
developed and solvents applied. Theoretically, 
the sensitivities of some of the earliest developed 
methods are higher than the present method; 
however, most of them are too expensive and 
cumbersome to be used in the routine assay of 
timolol especially in developing economies where 
their procurement, expertise and maintenance 




Table 5: Comparison of validated parameters of timolol assay 
 
Method Validated assay parameters Ref. 
Chemometric (CLS, 
PCR, PLS) 
ʎ max 295 nm, % mean recovery 99.85, % S.E 1.0, R2 0.9727-0.9993, ʎ max 
234-377 nm, IC95 93.67-105.75 %. 
[6]† 
Vierordt’s and bivariate 
calibration algorithm 
spectrophotometry 
ʎ max 257 nm, linearity 5-85 ppm, R2 0.9999, LOD 1.40-1.47 ppm, accuracy 
99.9-100.3 %, precision (SD) 0.702-0.996, %RSD 0.700-0.967, % error 0.221-
0.306, repeatability 99.7-100.5, specificity 100.2-100.6 %,  
[7]† 
Charge transfer ʎ max 543 nm, linearity 6.7-24.8 ppm, molar absorbance 0.6 l/mol.cm, R2 
0.99702, LOD 0.129692 ppm, LOQ 0.431873 ppm, precision % RSD 
(interday) 0.349-0.505 % intraday 0.39-0.78 % , recovery (serum) 99-




method, First Derivative 
Method and Ratio First 
Derivative UV 
spectrophotometry 
ʎ max 255-294; 302.3; 290 nm, linearity 2-50; ppm, R2 0.996-0.998, LOD 0.24-
0.5; 0.14; 0.091 ppm, LOQ 0.1515-0.727; 0.424, 0.276 ppm, recovery 98.94-
100.8; 99.73-101.1; 99.26-100.36 %, repeatability RSD 0.369-0.734; 1.02; 
0.696 %, RSD precision (interday) 0.329-0.940; 0.603-1.376; 0.388-0.870 % 
(intraday) 0.165-0.722; 0.276- 0.361; 0.298-0.379 % 
[8]† 
TLC-densitometry ʎ max 294 nm, linearity 1000-6000 ng/spot, recovery 99.87 %, RSD precision 
(intraday) 0.74-1.42 % (interday) 1.15-1.46 %, recovery 99.75-99.96 % 
[16] 
RP-HPLC ʎ max 285 nm, linearity 5-30 ppm, recovery 99.75-100.06 %, LOD 1.24 ppm,  
LOQ 3.77 ppm, robustness RSD 0.053-0.260 %, regression y=47.28x-15.57, 
R2 0.999, precision RSD (interday) 0.04 (intraday) 0.16, commercial drug 
estimate 100.42 %. 
[18]† 
UV spectrophotometry ʎ max 295 nm, linearity 2-10 ppm, regression equation y=0.0258x-0.00076, R2 
0.9999, LOQ 1.0 ppm. 
[9] 
RP-HPLC ʎ max 295 nm, linearity 10-20 ppm, precision RSD (intraday) 1.24-1.68 % 
(interday) 1.31-1.86 %, recovery 97.3-99.4 %. LOQ 1.4 ppm, R2 0.989, 
regression equation y=35.56x-10.49, LOD 0.4 ppm. 
[12] 
RP-HPLC ʎ max 210 nm, linearity 250-750 ppm, LOD 0.3 ppm, LOQ 0.8 ppm, regression 
equation y=17537.67x+59803.88, R2 0.9994, precision RSD 0.09 %, recovery 
99.9-100.1 %. 
[20] 
RP-HPLC ʎ max 295 nm, linearity 10-30 ppm, regression equation y=16109x-48294, R2 
0.999, LOD 0.755 ppm, LOQ 2.289 ppm, precision RSD (intraday) 0.788 





ʎ max 295 nm, linearity 3-20 ppm, regression equation y=0.0394x-0.002, R2 





Tables 2-4 † 
Classical least square (CLS), principal components regression (PCR), partial least square (PLS), †developed 
methods successfully applied to commercial timolol dosage forms 
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The developed method is simple, rapid, 
sensitive, reproducible, accurate and economical 
for assay of timolol compared to some 
chromatographic methods earlier developed. The 
probable mechanism of oxidation is by S-
oxidation with little or no contribution from the 
morpholine ring oxidation. The method should be 
suitable in quality control and assurance for rapid 
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